<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455907</url>
  </required_header>
  <id_info>
    <org_study_id>2017_51</org_study_id>
    <secondary_id>2017-A03012-51</secondary_id>
    <nct_id>NCT03455907</nct_id>
  </id_info>
  <brief_title>Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer</brief_title>
  <acronym>BEVARTHRALGIA</acronym>
  <official_title>Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Self-administered questionnaire survey to determine the presence or absence of joint pain
      during bevacizumab treatment for lung, ovarian, colorectal cancers.

      The principal end-point is the frequency of arthralgia after 6 months of treatment with
      Bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of arthralgia</measure>
    <time_frame>At 6 months</time_frame>
    <description>Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between global cancer response and occurrence of arthralgia</measure>
    <time_frame>baseline, at 3 months, at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>auto questionnaire specific to the study</measure>
    <time_frame>Baseline at 3 months, at 6 months</time_frame>
    <description>16 questions concerning the location, intensity, management of joint pain</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arthralgia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Bevacizumab for Lung, ovarian or colorectal cancers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy

          -  Male or female (aged ≥18 years old)

          -  Performance Status (PS) between 0 and 2

          -  Expected life&gt; 3 months

          -  Ability to answer a self-questionnaire

          -  Obtaining the non-opposition of patient participation

        Exclusion Criteria:

          -  Pregnant or lactating woman

          -  Rapid evolution of neoplastic pathology

          -  Major cognitive disorders that do not allow filling of the self-questionnaire

          -  Impossibility to submit to medical monitoring for social, psychological or
             geographical reasons

          -  Patients under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Hélène Viellard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Hélène Vieillard, MD</last_name>
    <phone>3.20.44.40.58</phone>
    <phone_ext>+33</phone_ext>
    <email>mh.vieillard@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diane PANNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez. CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony TURPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

